Categories: Market Research

Duchenne Muscular Dystrophy Market Size, Share, Growth, Trends and Forecast 2033

Overview and Scope
Duchenne muscular dystrophy is a genetic disease that causes gradual muscle loss, affecting the skeletal, cardiac, and lung muscles. It is caused by a mutation in the gene responsible for producing dystrophin, a protein that is crucial for the healthy operation of muscles.

Sizing and Forecast
The duchenne muscular dystrophy market size has grown strongly in recent years. It will grow from $1.07 billion in 2023 to $1.17 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to genetic understanding and diagnostic advances, clinical trial progress, patient advocacy and awareness, orphan drug designation and incentives, collaborative research initiatives.

The duchenne muscular dystrophy market size is expected to see strong growth in the next few years. It will grow to $1.61 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to emerging gene therapies, precision medicine approaches, expanded access to therapies, long-term follow-up studies, regulatory advancements. Major trends in the forecast period include integration of digital health technologies, technological advancements in therapeutics, gene therapies and genetic medicines, regulatory support for orphan drugs, precision medicine approaches.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-global-market-report

The duchenne muscular dystrophy market covered in this report is segmented –

1) By Therapy: Mutation Suppression, Exon Skipping Approach
2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy
3) By Route of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

North America was the largest region in the Duchenne muscular dystrophy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in the duchenne muscular dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10368&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of chronic diseases is expected to propel the growth of the Duchenne muscular dystrophy market in the future. A chronic disease is a health issue or condition with long-lasting symptoms lasting for at least a year. The Duchenne muscular dystrophy contributes to the prevalence of chronic diseases by addressing the specific therapeutic needs of individuals with this genetic disorder, highlighting the broader significance of personalized medicine in managing and potentially mitigating the impact of chronic conditions. For instance, in January 2023, according to the National Institutes of Health (NIH), a U.S. government agency that conducts and supports biomedical and health-related research, the study projects a substantial rise in the prevalence of chronic diseases among the working-age population in the United States, with an estimated 99.5% increase in adults aged 50 years and older with at least one chronic disease from 2020 to 2035. Additionally, the prevalence of multimorbidity is expected to surge by 110.5% from 2020 to 2050, highlighting the growing health challenges faced by the working population. Therefore, the increasing prevalence of chronic diseases is driving the growth of the Duchenne muscular dystrophy market.

Key Industry Players
Major companies operating in the duchenne muscular dystrophy market report are Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, PerkinElmer Inc., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Acceleron Pharma Inc., FibroGen Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., CureVac N.V., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., Nihon Pharmaceutical Co. Ltd., WAVE Life Sciences Ltd., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc.

The duchenne muscular dystrophy market report table of contents includes:

1. Executive Summary

2. Duchenne Muscular Dystrophy Market Characteristics

3. Duchenne Muscular Dystrophy Market Trends And Strategies

4. Duchenne Muscular Dystrophy Market – Macro Economic Scenario

…………..

32. Global Duchenne Muscular Dystrophy Market Competitive Benchmarking

33. Global Duchenne Muscular Dystrophy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy Market

35. Duchenne Muscular Dystrophy Market Future Outlook and Potential Analysis

36. Appendix

Contact Us: